<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752267</url>
  </required_header>
  <id_info>
    <org_study_id>6B-20-1</org_study_id>
    <secondary_id>NCI-2021-00706</secondary_id>
    <secondary_id>6B-20-1</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT04752267</nct_id>
  </id_info>
  <brief_title>18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases</brief_title>
  <official_title>Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial tests the use of a radioactive tracer (a drug that is visible during&#xD;
      an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed&#xD;
      tomography (PET/CT) in patients with brain cancer or cancer that has spread to the brain&#xD;
      (brain metastases). A PET/CT scan is an imaging test that uses a small amount of radioactive&#xD;
      tracer (given through the vein) to take detailed pictures of areas inside the body where the&#xD;
      tracer is taken up. 18F-FMAU may also help find the cancer and how far the disease has&#xD;
      spread. Magnetic resonance imaging (MRI) is a type of imaging test used to diagnose brain&#xD;
      tumors. 18F-FMAU PET/CT in addition to MRI may make the finding and diagnosing of brain tumor&#xD;
      easier.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the correlation between multiparametric magnetic resonance imaging (mpMRI)&#xD;
      radiomics and dynamic 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) PET kinetic&#xD;
      analysis parameters.&#xD;
&#xD;
      II. Explore the different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters&#xD;
      between patients with presence or absence of recurrent tumor.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes.&#xD;
      Patients then undergo standard of care mpMRI over approximately 45 minutes.&#xD;
&#xD;
      After completion of study intervention, patients are followed up at 24-96 hours after their&#xD;
      18F-FMAU PET/CT scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between multiparametric magnetic resonance imaging (mpMRI) radiomics and dynamic fluorine F 18 (18F)-FAMU (FMAU) positron emission tomography (PET) kinetic analysis parameters</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Scatter plots will be used to illustrate the pattern of correlation. For normality distributed data, Pearson correlation will be used; otherwise, Spearman correlation will be used. There will be 90 pairs of correlations. To further confirm the robustness of the correlation finding, the Benjamini-Hochberg procedure will be applied to prevent false discovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Interesting patterns will be observed at individual subject level for the difference between presence or absence of recurrent tumor, which defined as either underlying immunohistochemistry (Ki67-MIB proliferation marker, when tissue sample is available, or a binary proxy marker of subsequent clinical management decision (with wait-and-watch strategy for 1 month after imaging studies considered as &quot;absence&quot; of recurrent tumor, otherwise marked as &quot;presence&quot; of recurrent tumor). Heatmap will be used with subject identification as x-axis and each radiomic/kinetic feature as y-axis. Features will be divided by categories to facilitate the visualization of patterns.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Anatomic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Clinical Stage IV Cutaneous Melanoma AJCC v8</condition>
  <condition>Glioma</condition>
  <condition>Malignant Brain Neoplasm</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Metastatic Colon Carcinoma</condition>
  <condition>Metastatic Kidney Carcinoma</condition>
  <condition>Metastatic Lung Carcinoma</condition>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Pathologic Stage IV Cutaneous Melanoma AJCC v8</condition>
  <condition>Prognostic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Stage IV Colon Cancer AJCC v8</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IV Renal Cell Cancer AJCC v8</condition>
  <condition>Stage IVA Colon Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Colon Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <condition>Stage IVC Colon Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-FMAU, PET/CT, mpMRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (18F-FMAU, PET/CT, mpMRI)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FMAU</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (18F-FMAU, PET/CT, mpMRI)</arm_group_label>
    <other_name>Fluorine F 18 d-FMAU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multiparametric Magnetic Resonance Imaging</intervention_name>
    <description>Undergo mpMRI</description>
    <arm_group_label>Diagnostic (18F-FMAU, PET/CT, mpMRI)</arm_group_label>
    <other_name>MP-MRI</other_name>
    <other_name>mpMRI</other_name>
    <other_name>Multi-parametric MRI</other_name>
    <other_name>Multiparametric MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (18F-FMAU, PET/CT, mpMRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years, both men and women&#xD;
&#xD;
          -  Documented history of either primary brain tumor (e.g. glioma) or metastatic brain&#xD;
             tumor from another primary cancer (e.g. lung, breast, colon, melanoma, kidney)&#xD;
&#xD;
          -  Documented radiation therapy regardless of treatments prior to radiation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give consent&#xD;
&#xD;
          -  Inability to remain motionless during imaging studies&#xD;
&#xD;
          -  Intractable seizures&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Implantable devices incompatible with magnetic resonance (MR) environment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossein Jadvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjna Mani</last_name>
    <phone>323-442-7469</phone>
    <email>Sanjna.Mani@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjna Mani</last_name>
      <email>Sanjna.Mani@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Hossein Jadvar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

